Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births

BACKGROUND: In 2005, the FDA cautioned that exposure to paroxetine, a selective serotonin reuptake inhibitor (SSRI), during the first trimester of pregnancy may increase the risk of cardiac malformations. Since then, the association between maternal use of SSRIs during pregnancy and congenital malfo...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:BMC Med
Main Authors: Gao, Shan-Yan, Wu, Qi-Jun, Sun, Ce, Zhang, Tie-Ning, Shen, Zi-Qi, Liu, Cai-Xia, Gong, Ting-Ting, Xu, Xin, Ji, Chao, Huang, Dong-Hui, Chang, Qing, Zhao, Yu-Hong
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2018
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6231277/
https://ncbi.nlm.nih.gov/pubmed/30415641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-018-1193-5
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares